Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus

Investigational Site Number 392226, Amagasaki-Shi

Investigational Site Number 392218, Chigasaki-Shi

Investigational Site Number 392212, Chiyoda-Ku

Investigational Site Number 392208, Chuoh-Ku

Investigational Site Number 392209, Chūōku

Investigational Site Number 392210, Chūōku

Investigational Site Number 392217, Ebina-Shi

Investigational Site Number 392216, Fujisawa-Shi

Investigational Site Number 392222, Higashiosaka-Shi

Investigational Site Number 392223, Izumisano

Investigational Site Number 392215, Kamakura-Shi

Investigational Site Number 392225, Kashiwara-Shi

Investigational Site Number 392205, Kawagoe-Shi

Investigational Site Number 392204, Kawaguchi-Shi

Investigational Site Number 392206, Kisarazu-Shi

Investigational Site Number 392201, Koriyama-Shi

Investigational Site Number 392228, Kurashiki-Shi

Investigational Site Number 392229, Matsuyama

Investigational Site Number 392230, Matsuyama

Investigational Site Number 392211, Mitaka-Shi

Investigational Site Number 392220, Nagoya

Investigational Site Number 392227, Nishinomiya-Shi

Investigational Site Number 392203, Ogawa-Machi, Hikigun

Investigational Site Number 392231, Okawa-Shi

Investigational Site Number 392224, Osaka

Investigational Site Number 392207, Shinjuku-Ku

Investigational Site Number 392219, Shizuoka

Investigational Site Number 392221, Takatsuki-Shi

Investigational Site Number 392202, Ushiku-Shi

Investigational Site Number 392213, Yokohama

Investigational Site Number 392214, Yokohama